Literature DB >> 241613

Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.

J G Allen, P B East, R J Francis, J L Haigh.   

Abstract

A high proportion of an oral dose of 14C-debrisoquine sulfate is excreted in the urine by rat and man. The urinary radioactivity consists of a mixture of unchanged drug and polar, water-soluble metabolites which cannot be extracted into organic solvents. Treatment of methanolic extracts of the freeze dried urine with acetylacetone incorporates the amidino group of debrisoquine and these metabolites into a 4,6-dimethylpyrimidine ring, and yields derivatives which can be readily extracted from aqueous solution. Gas-liquid chromatographic-mass spectrometric studies of these extracts have shown that in both species: 1) the major metabolite is formed by 4-hydroxylation of debrisoquine; 2) a significant proportion of the dose is excreted as acidic metabolites, formed by opening the tetrahydroisoquinoline ring; 3) trace amounts of phenolic metabolites (5-, 6-, 7-, and 8-hydroxydebrisoquines) are also excreted.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 241613

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

Review 1.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

2.  Why hypertensive patients vary in their response to oral debrisoquine.

Authors:  J H Silas; M S Lennard; G T Tucker; A J Smith; S L Malcolm; T R Marten
Journal:  Br Med J       Date:  1977-02-12

Review 3.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

4.  The disposition of debrisoquine in hypertensive patients.

Authors:  J H Silas; M S Lennard; G T Tucker; A J Smith; S L Malcolm; T R Marten
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

5.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

6.  Potential role of CYP2D6 in the central nervous system.

Authors:  Jie Cheng; Yueying Zhen; Sharon Miksys; Diren Beyoğlu; Kristopher W Krausz; Rachel F Tyndale; Aiming Yu; Jeffrey R Idle; Frank J Gonzalez
Journal:  Xenobiotica       Date:  2013-04-25       Impact factor: 1.908

7.  The metabolism of [14C]-debrisoquine in man.

Authors:  J R Idle; A Mahgoub; M M Angelo; L G Dring; R Lancaster; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

8.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

Authors:  G C Kahn; A R Boobis; S Murray; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 9.  LC-MS-based metabolomics in drug metabolism.

Authors:  Chi Chen; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

Review 10.  Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.

Authors:  R T Coutts
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.